EGFR and cancer: The effect of sorafenib, bevacizumab, panitumumab, ramucirumab, sorafenib- bevacizumab, sorafenib-panitumumab and sorafenib-ramucirumab on the protein expression of cleaved CASPASE3, VEGFR2 and EGFR in HepG2 cancer cells was determined by western blot using GAPDH as a normalizer (Fig. 9).